TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32063465

Group type: EXPERIMENTAL
Intervention: Rotarex
Number of subjects: 2

Group type: COMPARATOR
Intervention: Angiojet
Number of subjects: 2
Study: 32707561

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg·kg body weight‐1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Placebo (6 mg·kg‐1 dextrose)
Number of subjects: 26
Study: 34617375

Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg) added to insulin therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 33713208

Group type: EXPERIMENTAL
Intervention: Cotton (Bt RCH‐2) exposed to 200 mg/kg soil Cd
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cotton (Bt RCH‐2) exposed to 0 mg/kg soil Cd (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cotton (Bt RCH‐2) exposed to various higher levels of Cd (200, 400, 600, 800, and 1000 mg/kg soil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plant-microbe interaction with Aspergillus awamori
Number of subjects: 0
Study: 32886536

Group type: EXPERIMENTAL
Intervention: Mandatory twice‐weekly clinical evaluation
Number of subjects: 311

Group type: COMPARATOR
Intervention: Standard once‐weekly clinical evaluation
Number of subjects: 311
Study: 33063477

Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg once daily for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 34214937

Group type: EXPERIMENTAL
Intervention: Tucatinib
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Tucatinib (in patients with brain metastases)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo (in patients with brain metastases)
Number of subjects: 364
Study: 35477877

Group type: EXPERIMENTAL
Intervention: Video consultations
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 34331766

Group type: EXPERIMENTAL
Intervention: Enhanced physical therapy interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care physical therapy
Number of subjects: 0
Study: 35088177

Group type: EXPERIMENTAL
Intervention: Patient-specific femoral alignment guide (PSG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional pre-operative planning
Number of subjects: 80
Study: 33481341

Group type: EXPERIMENTAL
Intervention: Weekly CERA administration
Number of subjects: 120

Group type: COMPARATOR
Intervention: Biweekly CERA administration
Number of subjects: 120
Study: 34536278

Group type: EXPERIMENTAL
Intervention: Visual Art Therapy (VAT) - 12 sessions over 6 weeks
Number of subjects: 127

Group type: COMPARATOR
Intervention: Health Education - 6 sessions
Number of subjects: 127
Study: 33053010

Group type: EXPERIMENTAL
Intervention: Teaching foot self‐care educational intervention
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (simply evaluated)
Number of subjects: 109
Study: 36111921

Group type: EXPERIMENTAL
Intervention: Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: THRIVE
Number of subjects: 20
Study: 33495205

Group type: EXPERIMENTAL
Intervention: Supervised neuromuscular exercise (n = 36)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Waiting list control (n = 36)
Number of subjects: 72
Study: 32665460

Group type: COMPARATOR
Intervention: Community ART groups (3MC)
Number of subjects: 5336

Group type: COMPARATOR
Intervention: 6-monthly community distribution points (6MCD)
Number of subjects: 5336

Group type: COMPARATOR
Intervention: 3MF (control)
Number of subjects: 5336

Group type: COMPARATOR
Intervention: 3MC
Number of subjects: 5336

Group type: COMPARATOR
Intervention: 6MCD
Number of subjects: 5336
Study: 36028887

Group type: EXPERIMENTAL
Intervention: L-serine (3.0 g taken 30 min before bedtime for 2 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: L-serine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: L-serine and Placebo
Number of subjects: 33
Study: 34226572

Group type: EXPERIMENTAL
Intervention: Rhamnan sulphate (100 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32859235

Group type: EXPERIMENTAL
Intervention: Rifampin combination therapy with standard antimicrobial treatment (cloxacillin or vancomycin)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard antimicrobial treatment (cloxacillin or vancomycin) without rifampin
Number of subjects: 99
Study: 35500962

Group type: COMPARATOR
Intervention: Extension-oriented exercises (EE)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Extension exercises plus neurodynamic exercises (EEN)
Number of subjects: 31
Study: 32356926

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34213957

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (170 μg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low-dose vitamin D3 (20 μg)
Number of subjects: 48
Study: 33471730

Group type: EXPERIMENTAL
Intervention: Technosphere insulin (TI)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Insulin aspart (IA)
Number of subjects: 309
Study: 35151026

Group type: EXPERIMENTAL
Intervention: Active PBM (30 J per site)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (passive recovery)
Number of subjects: 39
Study: 33145864

Group type: EXPERIMENTAL
Intervention: 15 g/day of E. angustifolia fruit powder
Number of subjects: 58

Group type: COMPARATOR
Intervention: 15 g/day of isomalt + corn starch (placebo)
Number of subjects: 58
Study: 35360929

Group type: COMPARATOR
Intervention: Lobar hemorrhage
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Deep hemorrhage
Number of subjects: 728
Study: 34064426

Group type: EXPERIMENTAL
Intervention: Focal knee joint cooling (FKJC) for 20 minutes
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control condition (plastic ice bag filled with candy corn) for 20 minutes
Number of subjects: 21
Study: 32121075

Group type: EXPERIMENTAL
Intervention: Consumption of unprocessed or minimally processed foods
Number of subjects: 1919

Group type: EXPERIMENTAL
Intervention: Higher intake of processed foods
Number of subjects: 1919

Group type: EXPERIMENTAL
Intervention: Consumption of ultra-processed food and drinks
Number of subjects: 1919

Group type: EXPERIMENTAL
Intervention: Consumption of unprocessed/minimally processed foods (high-grade cancers)
Number of subjects: 1919

Group type: EXPERIMENTAL
Intervention: Higher intake of processed foods (high-grade cancers)
Number of subjects: 1919
Study: 34460285

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Enhanced Standard Community Treatment (ESCT)
Number of subjects: 68
Study: 34592624

Group type: EXPERIMENTAL
Intervention: Adjunct yoga therapy (YG; n = 35)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Waitlist control group (WG; n = 33)
Number of subjects: 68
Study: 32532144

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention to reduce CVD events including drug therapy, lifestyle changes, and adherence support.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention to reduce CVD events.
Number of subjects: 67
Study: 34412033

Group type: EXPERIMENTAL
Intervention: EDU‐ACT
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 32107532

Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine plus ritonavir-boosted atazanavir
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 228
Study: 32366996

Group type: EXPERIMENTAL
Intervention: 1-week levofloxacin/dexamethasone eye drops followed by 1-week dexamethasone alone
Number of subjects: 808

Group type: COMPARATOR
Intervention: 2-week tobramycin/dexamethasone eye drops
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 808
Study: 36466503

Group type: EXPERIMENTAL
Intervention: Complete group (n = 653)
Number of subjects: 6030

Group type: EXPERIMENTAL
Intervention: Rate of AKI alerts detected by attending physicians (continuity variable)
Number of subjects: 6030
Study: 33403821

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 0
Study: 36479595

Group type: EXPERIMENTAL
Intervention: Metformin (1,000 mg, twice daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Alogliptin (25 mg, once daily)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 84
Study: 33438271

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Conventional cow's milk–based formula
Number of subjects: 1106
Study: 32532766

Group type: EXPERIMENTAL
Intervention: Negatively framed life expectancy statement
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Anchoring bias intervention
Number of subjects: 271
Study: 34517434

Group type: EXPERIMENTAL
Intervention: FMDAP (full-mouth disinfection with adjuvant erythritol air-polishing)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: FMD (full-mouth disinfection)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: FMS (full-mouth scaling)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Q-SRP (quadrant-wise scaling and root planing)
Number of subjects: 172
Study: 32633854

Group type: EXPERIMENTAL
Intervention: Fat grafting
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fat grafting with PRP
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (podiatry)
Number of subjects: 32
Study: 32949984

Group type: EXPERIMENTAL
Intervention: L-glutamine
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Other metabolites
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Quinolinic acid
Number of subjects: 705
Study: 32409760

Group type: EXPERIMENTAL
Intervention: Flavonoids (Group A, n=73)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Centella (Group B, n=66)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine treatment (Control Group C, n=60)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Flavonoids (Group A)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Centella (Group B)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine treatment (Control Group C)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Flavonoids
Number of subjects: 130
Study: 35905031

Group type: EXPERIMENTAL
Intervention: Engagement in exercise after hospitalization
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Self-efficacy for exercise at 6 months post-discharge
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Higher levels of functional ability at discharge
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Living with a partner
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Engagement in exercise prior to hospital admission
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: College or university education
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Exercise prior to hospital admission
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Living with a partner at discharge
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Higher functional ability at discharge
Number of subjects: 292
Study: 35048310

Group type: EXPERIMENTAL
Intervention: Mobilizing our Voices for Empowerment (MOVE)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Comparison health promotion intervention
Number of subjects: 54
Study: 34427806

Group type: EXPERIMENTAL
Intervention: 12-week supervised exercise intervention
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 260
Study: 32237945

Group type: EXPERIMENTAL
Intervention: Combination treatment (terazosin and nifedipine)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 165
Study: 35287231

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study: 36373413

Group type: EXPERIMENTAL
Intervention: ACT with Compassion (ACTwC)
Number of subjects: 5
Study: 33336889

Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil (PR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propofol only (PP)
Number of subjects: 50
Study: 32416926

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 35876236

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 33641624

Group type: EXPERIMENTAL
Intervention: Inspired Life Programme (ILP), a 10-session group-based multicomponent positive psychology intervention
Number of subjects: 18
Study: 32438479

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cinacalcet
Number of subjects: 24
Study: 34924275

Group type: EXPERIMENTAL
Intervention: CFSAT plus speed focused CCT
Number of subjects: 117

Group type: COMPARATOR
Intervention: CFSAT training alone
Number of subjects: 117
Study: 33260142

Group type: EXPERIMENTAL
Intervention: Quinine 1 (25-ml solution, 2 mM of quinine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quinine 2 (replicate of Quinine 1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Placebo (25-ml sweet-tasting no-carbohydrate solution)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (25 ml of water)
Number of subjects: 12
Study: 32108529

Group type: EXPERIMENTAL
Intervention: Microdosing LSD (13 mcg, 11.3% of one tab)
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Microdosing psilocybin (0.3 g of dried psilocybin mushrooms)
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Microdosing (LSD or psilocybin)
Number of subjects: 909
Study: 35915040

Group type: EXPERIMENTAL
Intervention: Yoga with slow breathing instructions (Vinyasa)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Yoga with no breathing instructions
Number of subjects: 54

Group type: COMPARATOR
Intervention: Seated rest with slow breathing instructions
Number of subjects: 54

Group type: COMPARATOR
Intervention: Seated rest with no breathing instructions
Number of subjects: 54
Study: 33615980

Group type: EXPERIMENTAL
Intervention: Economic status (b: −12.37; p < .001)
Number of subjects: 3094

Group type: EXPERIMENTAL
Intervention: Age (b: 0.90; p: 0.021)
Number of subjects: 3094

Group type: COMPARATOR
Intervention: Economic status (b: -21.1; p < .001)
Number of subjects: 3094

Group type: EXPERIMENTAL
Intervention: Concentration index (C)
Number of subjects: 3094

Group type: EXPERIMENTAL
Intervention: ECSU in the poor
Number of subjects: 3094

Group type: EXPERIMENTAL
Intervention: ECSU in the rich
Number of subjects: 3094

Group type: EXPERIMENTAL
Intervention: Gap between rich and poor
Number of subjects: 3094

Group type: EXPERIMENTAL
Intervention: Explained portion
Number of subjects: 3094

Group type: EXPERIMENTAL
Intervention: Unexplained portion coefficient
Number of subjects: 3094
Study: 32751269

Group type: EXPERIMENTAL
Intervention: 4 g OBG varying in MW and viscosity
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (200 mL water alone)
Number of subjects: 16
Study: 36057214

Group type: EXPERIMENTAL
Intervention: Tegaderm™
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Tegaderm™
Number of subjects: 0
Study: 33836004

Group type: EXPERIMENTAL
Intervention: Chikungunya virus (CHIKV) serology positive
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Symptoms consistent with chikungunya
Number of subjects: 377
Study: 35081272

Group type: EXPERIMENTAL
Intervention: Protein-rich diet
Number of subjects: 156

Group type: COMPARATOR
Intervention: Carbohydrate-rich diet
Number of subjects: 156
Study: 34333922

Group type: EXPERIMENTAL
Intervention: Sacral magnetic stimulation (SMS) combined with bladder function training, awakening training, and life and psychological intervention
Number of subjects: 57
Study: 34511588

Group type: EXPERIMENTAL
Intervention: Filtek Z500 composite
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Filtek Bulk Fill composite
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ketac Universal (high-viscosity glass ionomer cement)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Matrix systems (Tofflemire, AutoMatrix, matrix band with ring, contoured sectional matrix)
Number of subjects: 12
Study: 35500594

Group type: EXPERIMENTAL
Intervention: Village doctor-led multifaceted intervention
Number of subjects: 33995

Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 33995
Study: 34098980

Group type: EXPERIMENTAL
Intervention: Opuntia ficus-indica juice (OFI)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 33089713

Group type: EXPERIMENTAL
Intervention: Active CO2-laser treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 58
Study: 35643855

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Standard-of-care chemotherapy (SoC)
Number of subjects: 326
Study: 34616460

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-List Group (WLG)
Number of subjects: 60
Study: 34521609

Group type: EXPERIMENTAL
Intervention: Decitabine plus talacotuzumab
Number of subjects: 309

Group type: COMPARATOR
Intervention: Decitabine alone
Number of subjects: 309
Study: 32308631

Group type: EXPERIMENTAL
Intervention: Psychological online intervention (POI) with mindfulness module
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Psychological online intervention (POI)
Number of subjects: 55
Study: 36154981

Group type: EXPERIMENTAL
Intervention: Biological mesh
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Synthetic mesh
Number of subjects: 24
Study: 34473420

Group type: EXPERIMENTAL
Intervention: Co-supplementation of omega-3 and vitamin D
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168

Group type: COMPARATOR
Intervention: Omega-3
Number of subjects: 168

Group type: COMPARATOR
Intervention: Vitamin D
Number of subjects: 168
Study: 32659365

Group type: EXPERIMENTAL
Intervention: Decompression with Interlaminar Stabilization (ILS)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Decompression with fusion
Number of subjects: 141

Group type: COMPARATOR
Intervention: Decompression with Interlaminar Stabilization (ILS) in patients <age 65
Number of subjects: 141
Study: 35027012

Group type: EXPERIMENTAL
Intervention: Group A (60% FiO2 and 0.1 µg/kg PGE1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group B (40% FiO2 and 0.1 µg/kg PGE1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group C (40% FiO2 and 0.2 µg/kg PGE1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no PGE1)
Number of subjects: 90
Study: 32163923

Group type: EXPERIMENTAL
Intervention: Jump-Rope Training (2-4 sessions/week, 10-20 minutes/week for 10 weeks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control warm-up routine
Number of subjects: 96
Study: 32734819

Group type: EXPERIMENTAL
Intervention: Tobacco cigarette (TC) smoking
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Electronic cigarette with nicotine (ECN)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Electronic cigarette without nicotine (EC0)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Nicotine inhaler (NI)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Baseline FMD
Number of subjects: 136
Study: 36177851

Group type: EXPERIMENTAL
Intervention: pIONM (n=90)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control (n=99)
Number of subjects: 189
Study: 32559027

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (2.0 mg/kg, i.p.) in mice
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.3 mg/kg, p.o.) in humans
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dextroamphetamine (0.3 mg/kg, p.o.)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine administration
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: mGlu5 expression in drug-naïve mice
Number of subjects: 70
Study: 32251932

Group type: EXPERIMENTAL
Intervention: Professional development intervention program (with and without parental-awareness meetings)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 444
Study: 35536828

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 120
Study: 32692113

Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART)
Number of subjects: 333
Study: 33094550

Group type: EXPERIMENTAL
Intervention: PROPESS (dinoprostone vaginal insert) for a maximum of 12 h
Number of subjects: 114
Study: 33471681

Group type: EXPERIMENTAL
Intervention: 30 mg/day prednisone for 1 week followed by 1 week of nonsteroidal anti-inflammatory drugs
Number of subjects: 50

Group type: COMPARATOR
Intervention: 6-week prednisone therapy
Number of subjects: 50
Study: 33188874

Group type: EXPERIMENTAL
Intervention: Utidelone plus capecitabine (30 mg/m2 IV daily, days 1-5, over 90 min; capecitabine 1000 mg/m2 orally b.i.d., days 1-14)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Capecitabine alone (1250 mg/m2 orally b.i.d., days 1-14)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Utidelone plus capecitabine
Number of subjects: 405

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 405
Study: 33129015

Group type: EXPERIMENTAL
Intervention: Hormonal treatment + electrotherapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Only hormonal treatment (control)
Number of subjects: 101
Study: 35344064

Group type: EXPERIMENTAL
Intervention: Group A (Arciero technique)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Group B (LaPrade technique)
Number of subjects: 19
Study: 34931372

Group type: EXPERIMENTAL
Intervention: Hyzetimibe (HS-25)
Number of subjects: 24